MEDISPA.PRO
Ministry of Health code: A11.12.003 Axis M2 · Detoxification and biotransformation CEBM: Level C (Infusion therapy (IV therapy))

Intravenous administration of glutathione

Intravenous Glutathione

Industry clinical and economic procedure passport. Full biological mechanism (MoA), patient preparation protocol, first-choice equipment fleet, integration into the resort's master treatment rooms and market price benchmarks.

To the procedure catalogue Equipment fleet Integration treatment rooms Rates and economics
Session duration
30 min
Turnover: ~45 min
Recommended course
10 sessions
10 treatments – an assumption for the economic calculation; the course is prescribed by a physician
Throughput capacity
11 pts
per 8-hour shift
Median rate
2 400 ₽
2 325 ₽ – 5 925 ₽
Course cost
24 000 ₽
at market median
Publication volume
Level C
4 publ. in PubMed

Clinical profile

Intravenous glutathione is a popular "detox" and "lightening" drip. Few clinical studies have been published: in a pilot RCT in Parkinson's disease, differences from placebo were not statistically significant, and a systematic review on skin lightening favours topical and oral glutathione because of the adverse effects of the intravenous route.

Every statement links to a publication in the list below. This is a snapshot of published research, not a final assessment of the method: international practice and integrated protocols often run ahead of official publications. Draft based on published research; requires review by a physician. Revision: 2026-10-17.

Open questions and study limitations

  • Parkinson's disease: in a pilot double-blind RCT, differences from placebo on the UPDRS scale were not statistically significant. [1]
  • Data on glutathione in Parkinson's disease are preliminary: small samples, short courses, varying doses and routes of administration. [4]
  • Skin lightening: the authors of a 2025 systematic review do not recommend the intravenous route because of weak effect and adverse effects. [2]

Safety

  • Anaphylaxis and hepatotoxicity have been described; there are no standard dosages. [3]
Contraindications. Contraindications are determined by the physician according to the equipment or drug instructions; they are not given in study abstracts.

Equipment fleet and fit-out

Certified first-choice medical equipment and compatible device systems

Equipment registry
Base configuration (Hero Device)
Infusomat

Device platform with proven validation of the biological response. Includes built-in biofeedback sensor systems, patient protection protocols and precision dosing of exposure.

Certification: Russian Ministry of Health registration certificate / CE Medical Device Directive Class IIa/IIb.
Compatible platforms in the MEDISPA.PRO registry
Infusion pump
Medical device, Roszdravnadzor registration certificate / CE
In the registry →

Architectural integration and treatment rooms

Resort rooms housing the treatment station (with SanPiN norms and MEP loads)

All treatment rooms →
1.3.1 120.0 m² · Class B

Treatment room for intravenous infusions / treatment room / laser blood irradiation / ozone therapy room / blood UV irradiation (10 individual cubicles)

General therapeutic interventions and high-tech therapy · Equipment: 11 538 900 ₽

Treatment room passport →

Unit economics and resort price benchmarks

Market analysis based on a sample of premium sanatoriums, wellness hotels and preventive medicine clinics

Market price corridor
25th percentile (P25) 2 325 ₽
Market median 2 400 ₽
75th percentile (P75) 5 925 ₽

Median of prices in industry facilities' price lists, 2026

Basis of the price benchmark

Prices for this procedure appear in the price lists of 3 industry facilities; the median and interquartile range across facilities are shown (each facility counts once).

Evidence base

A pilot RCT with no significant effect has been published, along with reviews that assess the intravenous route cautiously.

Publication level C · Little data
  1. 1.
    Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease.
    Mov Disord, 2009 · RCT (pilot, double-blind) · PMID 19230029
    Parkinson's disease: over 4 weeks, differences from placebo were not statistically significant.
  2. 2.
    Glutathione as a skin-lightening agent and in melasma: a systematic review.
    Int J Dermatol, 2025 · Systematic review · PMID 39444151
    Skin lightening: the authors do not recommend intravenous glutathione because of weak effect and adverse effects.
  3. 3.
    Exploring the Safety and Efficacy of Glutathione Supplementation for Skin Lightening: A Narrative Review.
    Cureus, 2025 · Review · PMID 40013212
    Safety concerns: anaphylaxis and hepatotoxicity; no standard dosing.
  4. 4.
    The role of N-acetylcysteine and glutathione in the management of Parkinson's disease: a systematic review of oxidative biomarkers and clinical outcomes.
    Amino Acids, 2026 · Systematic review · PMID 41874704
    Parkinson's disease: evidence for glutathione and N-acetylcysteine is preliminary.

Publications were found in PubMed; titles and journals are given verbatim, conclusions are a brief summary of the abstracts under the conditions of the specific studies. The level shows the volume of published data, not the value of the method: A — Plenty of data: consistent systematic reviews and meta-analyses of RCTs; B — Some data: reviews or several RCTs, results are heterogeneous; C — Little data: single RCTs or controlled studies; D — Scarce data: mainly reviews, observational and experimental studies. The passport is updated as new work is published and with regard to international practice.